{
    "id": 18487,
    "fullName": "GPNMB positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "GPNMB positive indicates the presence of the GPNMB gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10457,
        "geneSymbol": "GPNMB",
        "terms": [
            "GPNMB",
            "HGFIN",
            "NMB",
            "PLCA3"
        ]
    },
    "variant": "positive",
    "createDate": "02/23/2016",
    "updateDate": "07/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, glembatumumab vedotin treatment resulted in an overall responsive rate (ORR) of 6% (5/83) in breast carcinoma patients with gpNMB-expressing tumors, compared to a 7% ORR (3/41) in the chemotherapy group (PMID: 25847941).",
            "molecularProfile": {
                "id": 18829,
                "profileName": "GPNMB positive"
            },
            "therapy": {
                "id": 3597,
                "therapyName": "Glembatumumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4670,
                    "pubMedId": 25847941,
                    "title": "EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847941"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, glembatumumab vedotin treatment resulted in an objective response rate (ORR) of 18% (5/28) in triple receptor negative breast cancer patients expressing gpNMB, compared to a 0% ORR (0/11) in the chemotherapy group (PMID: 25847941).",
            "molecularProfile": {
                "id": 18829,
                "profileName": "GPNMB positive"
            },
            "therapy": {
                "id": 3597,
                "therapyName": "Glembatumumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4670,
                    "pubMedId": 25847941,
                    "title": "EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847941"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18829,
            "profileName": "GPNMB positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}